| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LRP4 |
| Uniprot No | O75096 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1905aa |
| 氨基酸序列 | MRRQWGALLLGALLCAHGLASSPECACGRSHFTCAVSALGECTCIPAQWQCDGDNDCGDHSDEDGCILPTCSPLDFHCDNGKCIRRSWVCDGDNDCEDDSDEQDCPPRECEEDEFPCQNGYCIRSLWHCDGDNDCGDNSDEQCDMRKCSDKEFRCSDGSCIAEHWYCDGDTDCKDGSDEENCPSAVPAPPCNLEEFQCAYGRCILDIYHCDGDDDCGDWSDESDCSSHQPCRSGEFMCDSGLCINAGWRCDGDADCDDQSDERNCTTSMCTAEQFRCHSGRCVRLSWRCDGEDDCADNSDEENCENTGSPQCALDQFLCWNGRCIGQRKLCNGVNDCGDNSDESPQQNCRPRTGEENCNVNNGGCAQKCQMVRGAVQCTCHTGYRLTEDGHTCQDVNECAEEGYCSQGCTNSEGAFQCWCETGYELRPDRRSCKALGPEPVLLFANRIDIRQVLPHRSEYTLLLNNLENAIALDFHHRRELVFWSDVTLDRILRANLNGSNVEEVVSTGLESPGGLAVDWVHDKLYWTDSGTSRIEVANLDGAHRKVLLWQNLEKPRAIALHPMEGTIYWTDWGNTPRIEASSMDGSGRRIIADTHLFWPNGLTIDYAGRRMYWVDAKHHVIERANLDGSHRKAVISQGLPHPFAITVFEDSLYWTDWHTKSINSANKFTGKNQEIIRNKLHFPMDIHTLHPQRQPAGKNRCGDNNGGCTHLCLPSGQNYTCACPTGFRKISSHACAQSLDKFLLFARRMDIRRISFDTEDLSDDVIPLADVRSAVALDWDSRDDHVYWTDVSTDTISRAKWDGTGQEVVVDTSLESPAGLAIDWVTNKLYWTDAGTDRIEVANTDGSMRTVLIWENLDRPRDIVVEPMGGYMYWTDWGASPKIERAGMDASGRQVIISSNLTWPNGLAIDYGSQRLYWADAGMKTIEFAGLDGSKRKVLIGSQLPHPFGLTLYGERIYWTDWQTKSIQSADRLTGLDRETLQENLENLMDIHVFHRRRPPVSTPCAMENGGCSHLCLRSPNPSGFSCTCPTGINLLSDGKTCSPGMNSFLIFARRIDIRMVSLDIPYFADVVVPINITMKNTIAIGVDPQEGKVYWSDSTLHRISRANLDGSQHEDIITTGLQTTDGLAVDAIGRKVYWTDTGTNRIEVGNLDGSMRKVLVWQNLDSPRAIVLYHEMGFMYWTDWGENAKLERSGMDGSDRAVLINNNLGWPNGLTVDKASSQLLWADAHTERIEAADLNGANRHTLVSPVQHPYGLTLLDSYIYWTDWQTRSIHRADKGTGSNVILVRSNLPGLMDMQAVDRAQPLGFNKCGSRNGGCSHLCLPRPSGFSCACPTGIQLKGDGKTCDPSPETYLLFSSRGSIRRISLDTSDHTDVHVPVPELNNVISLDYDSVDGKVYYTDVFLDVIRRADLNGSNMETVIGRGLKTTDGLAVDWVARNLYWTDTGRNTIEASRLDGSCRKVLINNSLDEPRAIAVFPRKGYLFWTDWGHIAKIERANLDGSERKVLINTDLGWPNGLTLDYDTRRIYWVDAHLDRIESADLNGKLRQVLVSHVSHPFALTQQDRWIYWTDWQTKSIQRVDKYSGRNKETVLANVEGLMDIIVVSPQRQTGTNACGVNNGGCTHLCFARASDFVCACPDEPDSRPCSLVPGLVPPAPRATGMSEKSPVLPNTPPTTLYSSTTRTRTSLEEVEGRCSERDARLGLCARSNDAVPAAPGEGLHISYAIGGLLSILLILVVIAALMLYRHKKSKFTDPGMGNLTYSNPSYRTSTQEVKIEAIPKPAMYNQLCYKKEGGPDHNYTKEKIKIVEGICLLSGDDAEWDDLKQLRSSRGGLLRDHVCMKTDTVSIQASSGSLDDTETEQLLQEEQSECSSVHTAATPERRGSLPDTGWKHERKLSSESQV |
| 预测分子量 | 19.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LRP4重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Structural Basis of Agrin-LRP4-MuSK Signaling*
**作者**：Zhang, B. et al.
**摘要**：该研究解析了LRP4胞外域的重组蛋白结构，揭示了其与神经肌肉接头关键蛋白Agrin的相互作用机制，阐明了LRP4在MuSK信号激活中的构象变化，为相关疾病的治疗提供结构基础。
2. **文献名称**：*LRP4 is Critical for Wnt/β-Catenin Signaling during Vertebrate Development*
**作者**：Weatherbee, S.D. et al.
**摘要**：通过重组LRP4蛋白的体外功能实验，证明LRP4作为Wnt信号共受体，调控胚胎发育过程中的细胞分化，并验证其胞内结构域对信号转导的必要性。
3. **文献名称**：*Autoantibodies to LRP4 in Myasthenia Gravis: Humanization of a Recombinant Prototype*
**作者**：Higuchi, O. et al.
**摘要**：研究利用重组人源化LRP4蛋白，发现其与重症肌无力患者自身抗体的特异性结合，揭示了LRP4自身免疫反应在疾病发生中的作用，为诊断标志物开发奠定基础。
4. **文献名称**：*LRP4 Modulates Cancer Cell Migration through Receptor-Mediated Signaling*
**作者**：Gomez, A.M. et al.
**摘要**：该工作通过重组LRP4蛋白的细胞实验，证明其胞外域与肿瘤微环境中的配体相互作用，调控整合素信号通路，进而影响癌细胞的迁移和侵袭能力。
(注：上述文献信息为示例性质，实际引用时请核实原文准确性。)
**Background of LRP4 Recombinant Protein**
LRP4 (low-density lipoprotein receptor-related protein 4) is a transmembrane protein belonging to the LDL receptor family, which plays critical roles in cell signaling and communication. It is structurally characterized by extracellular LDLR domains, EGF-like repeats, and a cytoplasmic NPxY motif. LRP4 functions as a co-receptor in multiple pathways, most notably the bone morphogenetic protein (BMP) and Wnt signaling cascades. In neuromuscular biology, LRP4 interacts with agrin to activate MuSK (muscle-specific kinase), a key regulator of neuromuscular junction (NMJ) formation and maintenance. Dysregulation of LRP4 is implicated in congenital myasthenic syndromes, skeletal abnormalities, and certain cancers.
Recombinant LRP4 protein is engineered *in vitro* using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional LRP4 for research and therapeutic applications. This engineered protein retains critical domains for ligand binding and signaling, enabling studies on its interaction partners (e.g., agrin, Wnt ligands) and mechanisms in development and disease. For example, recombinant LRP4 is used to investigate NMJ defects or to screen for therapeutic agents targeting LRP4-associated disorders.
In cancer, LRP4 may act as a tumor suppressor or promoter depending on context, and recombinant forms help dissect its dual roles. Additionally, LRP4’s involvement in bone homeostasis has spurred interest in regenerative medicine. By providing a controlled source of functional protein, recombinant LRP4 accelerates structural studies, antibody development, and pathway analysis, bridging gaps between basic research and clinical translation.
Overall, LRP4 recombinant protein serves as a vital tool for unraveling the protein’s biological significance and advancing therapeutic strategies for related diseases.
×
